TapewireFind a company

person · Reporting owner

NEWELL WILLIAM J

Disclosed activity across 3 companies

Tapewire entity
82236
SEC CIK
0001309660

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
SUTRO BIOPHARMA, INC.STRO · Entity 5797Director · CEOMarch 05, 2025March 07, 2025
Social Capital Suvretta Holdings Corp. IVDNAD · Entity 123913DirectorSeptember 07, 2022September 09, 2022
Vaxcyte, Inc.PCVX · Entity 1164DirectorDecember 09, 2020December 11, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

SUTRO BIOPHARMA, INC.

Report date March 05, 2025 · Filed March 07, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect292,531 Ending reported balance After 2025-03-05 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2025-03-05 · Exercise / conversion · Acquired 18,750 · Balance 299,239

Row 2 · 2025-03-05 · Tax withholding · Disposed 6,708 · Balance 292,531

F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.

Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2025-03-05Direct0 Reported balance After 2025-03-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2025-03-05 · Exercise / conversion · Disposed 18,750 · Balance 0

F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.

F4: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date.

Common StockSEC Table I · non-derivativeIndirectBy William J. Newell Family Trust DTD 03/15/2019116,525 Reported balance Holding disclosure · report date 2025-03-05 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 116,525

F2: The securities are held of record by the reporting person as trustee of the William J. Newell Family Trust DTD 03/15/2019.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.

F2: The securities are held of record by the reporting person as trustee of the William J. Newell Family Trust DTD 03/15/2019.

F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.

F4: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date.

Social Capital Suvretta Holdings Corp. IV

Report date September 07, 2022 · Filed September 09, 2022

This filing explicitly reported no securities owned.

Vaxcyte, Inc.

Report date December 09, 2020 · Filed December 11, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect66,684 Reported balance After 2020-12-09 transaction · row 1
1 source row

Row 1 · 2020-12-09 · Grant · Acquired 22,228 · Balance 66,684

F1: Shares acquired by the reporting person from Sutro Biopharma, Inc. pursuant to the Sutro Biopharma, Inc. 2017 Call Option Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Shares acquired by the reporting person from Sutro Biopharma, Inc. pursuant to the Sutro Biopharma, Inc. 2017 Call Option Plan.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 01, 2021 Filed Sep 28, 2021 18:58 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 GiftCommon Stock 104,662 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-057981 · doc4.xml · nonDerivative · entry 2

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By William J. Newell Family Trust DTD 03/15/2019

Disclosed balance after: 104,662

F1 · ownership.nature: The securities are held of record by the reporting person as trustee of the William J. Newell Family Trust DTD 03/15/2019.

Read SEC document
July 01, 2021 Filed Sep 28, 2021 18:58 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 GiftCommon Stock 104,662 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-057981 · doc4.xml · nonDerivative · entry 1

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,687

Read SEC document
March 05, 2021 Filed Mar 8, 2021 17:20 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 GrantRestricted Stock Unit (RSU) · Derivative 75,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-018623 · doc4.xml · derivative · entry 2

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2025-03-05

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.

F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date.

Read SEC document
March 05, 2021 Filed Mar 8, 2021 17:20 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 GrantStock Option (right to buy Common Stock) · Derivative 200,000 $0.00 Strike: $21.11 $0.00
Disclosure

SEC source: 0001209191-21-018623 · doc4.xml · derivative · entry 1

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2031-03-04

F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on April 5, 2021, with 100% of the total shares vested and exercisable on March 5, 2025, subject to the reporting person's provision of service to the issuer on each vesting date.

Read SEC document
January 29, 2021 Filed Feb 1, 2021 17:56 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 Exercise / conversionRestricted Stock Unit (RSU) · Derivative 13,750 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-006559 · doc4.xml · derivative · entry 5

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,250

Underlying: Common Stock · 13,750 shares

Expires 2024-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.

F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date.

Read SEC document
January 29, 2021 Filed Feb 1, 2021 17:56 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 Tax withholdingCommon Stock 7,061 $22.15 $156,401.15
Disclosure

SEC source: 0001209191-21-006559 · doc4.xml · nonDerivative · entry 2

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,349

F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.

Read SEC document
January 29, 2021 Filed Feb 1, 2021 17:56 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 Exercise / conversionCommon Stock 13,750 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-006559 · doc4.xml · nonDerivative · entry 1

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,410

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 09, 2020 Filed Dec 11, 2020 01:39 UTC Vaxcyte, Inc. PCVX · Entity 1164 GrantCommon Stock 22,228 $1.29 $28,674.12
Disclosure

SEC source: 0001209191-20-062813 · doc4.xml · nonDerivative · entry 1

NEWELL WILLIAM J · CIK 0001309660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,684

F1 · kind: Shares acquired by the reporting person from Sutro Biopharma, Inc. pursuant to the Sutro Biopharma, Inc. 2017 Call Option Plan.

Read SEC document
September 25, 2020 Filed Sep 28, 2020 17:57 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 Exercise / conversionRestricted Stock Unit (RSU) · Derivative 25,252 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-052248 · doc4.xml · derivative · entry 5

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,253

Underlying: Common Stock · 25,252 shares

Expires 2021-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.

F5 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date.

Read SEC document
September 25, 2020 Filed Sep 28, 2020 17:57 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 Tax withholdingCommon Stock 13,219 $10.30 $136,155.70
Disclosure

SEC source: 0001209191-20-052248 · doc4.xml · nonDerivative · entry 2

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 178,660

F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.

Read SEC document
September 25, 2020 Filed Sep 28, 2020 17:57 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 Exercise / conversionCommon Stock 25,252 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-052248 · doc4.xml · nonDerivative · entry 1

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,879

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 11, 2020 Filed Jun 15, 2020 22:19 UTC Vaxcyte, Inc. PCVX · Entity 1164 GrantStock Option (right to buy) · Derivative 40,000 $0.00 Strike: $16.00 $0.00
Disclosure

SEC source: 0001209191-20-036742 · doc4.xml · derivative · entry 1

NEWELL WILLIAM J · CIK 0001309660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2030-06-10

F1 · derivative.exercise_date: 1/3 of the shares subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter.

Read SEC document
May 14, 2020 Filed May 14, 2020 17:29 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 PurchaseCommon Stock 64,516 $7.75 $499,999.00
Disclosure

SEC source: 0001209191-20-029246 · doc4.xml · nonDerivative · entry 1

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,627

Read SEC document
January 29, 2020 Filed Jan 31, 2020 17:20 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 GrantRestricted Stock Unit (RSU) · Derivative 55,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-005814 · doc4.xml · derivative · entry 5

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2024-01-29

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.

F6 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date.

Read SEC document
January 29, 2020 Filed Jan 31, 2020 17:20 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 GrantStock Option (right to buy Common Stock) · Derivative 125,000 $0.00 Strike: $10.09 $0.00
Disclosure

SEC source: 0001209191-20-005814 · doc4.xml · derivative · entry 4

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2030-01-29

F4 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 29, 2020, with 100% of the total shares vested and exercisable on January 29, 2024, subject to the reporting person's provision of service to the issuer on each vesting date.

Read SEC document
September 26, 2019 Filed Sep 30, 2019 17:26 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 Exercise / conversionRestricted Stock Unit (RSU) · Derivative 25,252 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-051124 · doc4.xml · derivative · entry 5

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,505

Underlying: Common Stock · 25,252 shares

Expires 2021-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.

F7 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date.

Read SEC document
September 26, 2019 Filed Sep 30, 2019 17:26 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 Tax withholdingCommon Stock 13,219 $9.74 $128,753.06
Disclosure

SEC source: 0001209191-19-051124 · doc4.xml · nonDerivative · entry 2

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,118

F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.

Read SEC document
September 26, 2019 Filed Sep 30, 2019 17:26 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 Exercise / conversionCommon Stock 25,252 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-051124 · doc4.xml · nonDerivative · entry 1

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,337

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Since the date of the reporting person's last ownership report, he transferred 94,085 shares of the issuer's common stock in a transfer exempt from Section 16. Following this transfer, the reporting person does not have voting or investment power over, or a pecuniary interest in, the transferred shares.

Read SEC document
January 29, 2019 Filed Jan 31, 2019 17:11 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 GrantStock Option (right to buy Common Stock) · Derivative 445,000 $0.00 Strike: $10.45 $0.00
Disclosure

SEC source: 0001209191-19-006206 · doc4.xml · derivative · entry 1

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 445,000

Underlying: Common Stock · 445,000 shares

Expires 2029-01-28

F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 28, 2019, with 100% of the total shares vested and exercisable on January 29, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.

Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:20 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 ConversionSeries B Preferred Stock · Derivative 50,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-052841 · doc4.xml · derivative · entry 7

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Newell Family Revocable Trust DTD 08/14/2008

Disclosed balance after: 0

Underlying: Common Stock · 2,890 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F3 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F3 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F4 · ownership.nature: These securities are held of record by the reporting person as trustee of the Newell Family Revocable Trust DTD 08/14/2008.

Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:20 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 ConversionSeries D Preferred Stock · Derivative 192,267 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-052841 · doc4.xml · derivative · entry 6

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,787 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F2 · derivative.exercise_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F2 · derivative.expiration_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:20 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 ConversionSeries C Preferred Stock · Derivative 55,657 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-052841 · doc4.xml · derivative · entry 5

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,059 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.

F1 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.

F1 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.

Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:20 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 ConversionCommon Stock 2,890 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-052841 · doc4.xml · nonDerivative · entry 3

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Newell Family Revocable Trust DTD 08/14/2008

Disclosed balance after: 21,154

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F4 · ownership.nature: These securities are held of record by the reporting person as trustee of the Newell Family Revocable Trust DTD 08/14/2008.

Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:20 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 ConversionCommon Stock 7,787 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-052841 · doc4.xml · nonDerivative · entry 2

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,170

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:20 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 ConversionCommon Stock 2,059 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-052841 · doc4.xml · nonDerivative · entry 1

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,383

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.

Read SEC document
September 26, 2018 Filed Sep 27, 2018 18:03 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 GrantRestricted Stock Unit (RSU) · Derivative 75,757 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-052492 · doc4.xml · derivative · entry 2

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,757

Underlying: Common Stock · 75,757 shares

Expires 2021-09-25

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.

F3 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date.

Read SEC document
September 26, 2018 Filed Sep 27, 2018 18:03 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 GrantStock Option (right to buy Common Stock) · Derivative 454,545 $0.00 Strike: $15.00 $0.00
Disclosure

SEC source: 0001209191-18-052492 · doc4.xml · derivative · entry 1

NEWELL WILLIAM J · CIK 0001309660 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 454,545

Underlying: Common Stock · 454,545 shares

Expires 2028-09-25

F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.